Cagrilintide

What is Cagrilintide?

Cagrilintide (development code AM833) is an investigational once-weekly injectable peptide from Novo Nordisk. It is a long-acting analog of amylin, a hormone co-secreted with insulin by the pancreas that helps regulate appetite and fullness. It has drawn the most attention as the amylin half of CagriSema, an investigational combination with semaglutide.

As of 2026, cagrilintide is not FDA-approved, either on its own or as part of CagriSema. It is a clinical-trial compound, not something a legitimate clinic can compound or dispense, and Strong Health does not provide it.

How Cagrilintide works

Amylin works alongside GLP-1 through a different pathway: it promotes satiety, slows gastric emptying, and helps regulate how quickly you feel full and how much you eat. Cagrilintide is engineered to mimic amylin with a long enough duration of action for once-weekly dosing.

The strategic interest in cagrilintide is combination therapy. Pairing an amylin analog (cagrilintide) with a GLP-1 agonist (semaglutide) engages two complementary appetite-regulating systems at once, which is the premise behind CagriSema and the reason cagrilintide is usually discussed in that context.

What Cagrilintide is used for

What the evidence shows

In a phase 2, randomized, double-blind, placebo- and active-controlled dose-finding trial published in The Lancet in 2021, once-weekly cagrilintide led to significant, dose-dependent weight loss in people with overweight and obesity and was generally well tolerated, with the highest dose (2.4 mg) producing roughly 10–11% weight reduction over the study period [1].

Cagrilintide's larger story is combination therapy: trials of CagriSema (cagrilintide plus semaglutide) have been the main driver of interest, testing whether dual amylin/GLP-1 action outperforms GLP-1 alone.

As with any investigational agent, phase 2 data establish a signal, not a settled treatment. Long-term safety, durability, and the full CagriSema outcome picture depend on phase 3 results, and we present this honestly rather than as an available therapy.

Dosing & administration context

In trials, cagrilintide is administered as a once-weekly subcutaneous injection with gradual dose escalation, and — in the combination program — co-administered with semaglutide. Trial dosing follows study protocols, not patient self-titration.

Because cagrilintide is investigational, there is no approved label, no approved dose, and no legitimate compounded or retail supply. Product sold online as 'cagrilintide' outside a trial is unverified for identity, purity, and sterility — the gray-market risk our clinical model exists to avoid.

Cagrilintide is investigational and not FDA-approved. This page is educational, physician-reviewed context — not medical advice, a dosing guide, or an offer to prescribe. Strong Health does not provide cagrilintide.

Safety & side effects

The most common side effects reported in trials are gastrointestinal — nausea, reduced appetite, and related symptoms — consistent with appetite-regulating therapies and generally dose-related. Injection-site reactions have also been reported.

Long-term safety is not established, since cagrilintide remains in development. Its complete risk profile and outcomes over years of use are not yet known, which is a central reason we do not offer it.

Why Strong Health does not offer Cagrilintide

Strong Health does not prescribe or provide cagrilintide or CagriSema. Both are investigational, not FDA-approved, and available only through clinical trials — not as compounded or research-grade products. Providing an unapproved novel molecule outside a trial would be inconsistent with the law and with our standards.

We document cagrilintide because patients ask about it and deserve a clear, physician-reviewed picture of where the evidence stands. For medically supervised weight loss now, our physicians evaluate FDA-cleared and appropriately compounded options and build a monitored protocol around your labs rather than chasing the newest unapproved compound.

Frequently asked questions